The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer

Urology

Volumn 71, Issue 1, 2008, Pages 151-155

  Heath, Elisabeth I ^a   Kattan, Michael W ^b   Powell, Isaac J ^a   Sakr, Wael ^a   Brand, Timothy C ^c   Rybicki, Benjamin A ^a,d   Thompson, Ian M ^c   Aronson, William J ^e   Terris, Martha K ^f   Kane, Christopher J ^g   Presti Jr , Joseph C ^h   Amling, Christopher L ⁱ   Freedland, Stephen J ^j  

^a KARMANOS CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ETHNICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RACE; UNITED STATES;

ADULT; AFRICAN AMERICANS; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 38649099364     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.08.016     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Stanford J.L., Stephenson R.A., Coyle L.M., et al. Prostate Cancer Trends 1973-1995: SEER Program, National Cancer Institute. NIH Pub. No. 99-4543 (1999), National Institutes of Health, Bethesda, Maryland
3. Gilligan T., Wang P.S., Levin R., et al. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 164 (2004) 1858-1864
4. Freedland S.J., and Isaacs W.B. Explaining racial differences in prostate cancer in the United States: sociology or biology?. Prostate 62 (2005) 243-252
5. Mohler J.L., Gaston K.E., Moore D.T., et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 171 (2004) 2277-2280
6. Shuch B., Mikhail M., Satagopan J., et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 22 (2004) 4725-4729
7. Stephenson A.J., and Kattan M.W. Nomograms for prostate cancer. BJU Int 98 (2006) 39-46
8. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
9. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
10. Freedland S.J., Amling C.L., Dorey F., et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670-674
11. Bianco Jr. F.J., Kattan M.W., Scardino P.T., et al. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol 170 (2003) 73-76 discussion 76-77
12. Rybicki B.A., Neslund-Dudas C., Nock N.L., et al. Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev 30 (2006) 412-422
13. Thompson K.E., Hernandez J., Canby-Hagino E.D., et al. Prognostic features in men who died of prostate cancer. J Urol 174 (2005) 553-556 discussion 556
14. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 (2000) 1591-1595
15. Aleman M., Karakiewicz P.I., Kupelian P., et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 62 (2003) 70-74
16. Eskicorapci S.Y., Karabulut E., Turkeri L., et al. Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol 47 (2005) 185-189
17. Garzotto M., and Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 159 (1998) 950-954 discussion 954-955
18. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
19. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
20. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
21. Cross C.K., Shultz D., Malkowicz S.B., et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 20 (2002) 2863-2868
22. Nielsen M.E., Han M., Mangold L., et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 176 (2006) 515-519
23. Bastian P.J., Gonzalgo M.L., Aronson W.J., et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107 (2006) 1265-1272
24. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
25. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
26. Freedland S.J., Terris M.K., Csathy G.S., et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 171 (2004) 2215-2220
27. Freedland S.J., Isaacs W.B., Platz E.A., et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 23 (2005) 7546-7554
28. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446-453
29. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012